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Systemic antibiotic therapy in persons with a diabetic foot infection (DFI) is frequent, increasing the risk of
promoting resistance to common pathogens. Applying principles of antibiotic stewardship may help avoid
this problem.
Recent findings
We performed a systematic review of the literature, especially seeking recently published studies, for data
on the role and value of antibiotic stewardship (especially reducing the spectrum and duration of antibiotic
therapy) in community and hospital populations of persons with a DFI.
Summary
We found very few publications specifically concerning antibiotic stewardship in persons with a DFI. The
case-mix of these patients is substantial and infection plays only one part among several chronic problems.
As with other types of infections, attempting to prevent infections and avoiding or reducing the spectrum
and duration of antibiotic therapy are perhaps the best ways to reduce antibiotic prescribing in the DFI
population. The field is complex and necessitates knowledge over the current scientific literature and
clinical experience. On a larger scale, clinical pathways, guidelines, and recommendations are
additionally supportive.
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Diabetic foot infections (DFIs) are associated with
substantial morbidity, frequent and prolonged hos-
pitalizations, a life-long risk for lower extremity
amputations, and high financial costs [1–4,5
&
,6].
Presented with a patient with a DFI, surgeons and
physician want to reduce the risk of poor clinical
outcomes. This often leads them to overprescribing
antibiotic therapy. This can take the form of pre-
scribing an unnecessarily broad-spectrum regimen
(often with combinations of agents), administering
parenteral rather than oral therapy, or continuing
therapy for a longer duration than necessary [1–
4,5
&
,6,7]. Although the clinicians concern about
failing to adequately treat infection is understand-
able, is not only ineffective but associated with risks
of adverse events, increased costs and promoting
antibiotic resistance. Furthermore, many fail to rec-
ognize the importance of other potentially impor-
tant therapeutic measures, such as pressure off-
loading or limb revascularization [5
&
]. Given how
common DFIs are, and how difficult they are to
treat, they are probably among the most frequentt © 2019 Wolters Kluwe
rs Kluwer Health, Inc. All rights resedisorders leading to antibiotic overuse worldwide
[8
&
,9].
This overuse of antimicrobial agents, while
unlikely to lead to better patient outcomes, does
result in both increased financial costs and adverse
clinical events [9,10]. Looking at the financial side of
this issue, annual direct medical costs related for
diabetes in the United States alone were estimated at
$176 billion in 2012 [11]. In a single hospital in
Trinidad and Tobago, cost for the care of only 446
patients with DFI was $14 million US dollars per year
[12], which the authors extrapolated to representr Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com
KEY POINTS
 DFIs are a major cause of antibiotic misuse and related
costs.
 Literature concerning antibiotic stewardship in DFIs is
sparse.
 Prevention of infections is an important cornerstone of
antibiotic stewardship.
 The individual reduction of inappropriate antibiotic use
still remains the practice.
 Other approaches, such as clinical pathways with
ordersets, are promising.
Skin and soft tissue infections0.4% of the entire gross domestic product of that
country. The direct antibiotic-related costs for a DFI
may add up to US $1000 US dollars in Australia, a
resource-rich country [13]. In a recent prospective
trial randomizing the use of topical gentamicin
sponges (together with systemic antibiotics) for
ulcerated DFIs, adverse events occurred at 23%
[14]. Looking at antibiotic-related adverse effects,
studies have reported high rates of kidney injuries
[15], selection of resistant pathogens such as methi-
cillin-resistant staphylococci or vancomycin-resis-
tant enterococci [16]. The incidence of antibiotic-
resistant pathogens reached 15% and the rate of
transient renal insufficiency reached 30% in one
recent study [15]. Other reported adverse antibi-
otic-related events include nausea, drug-induced
hepatitis, Clostridium difficile colitis [17]), and cen-
tral-line catheter-related problems from intravenous
therapy [15].
In 2016, a joint position paper by the British
Society for Antimicrobial Chemotherapy and the
European Wound Management Association [18]
offered recommendations for wound care, but did
not provide in-depth recommendations for antibi-
otic stewardship in DFIs. In this review, we will
summarize the literature related to antibiotic stew-
ardship in DFI. A review of the management of
multiresistant pathogens [19,20] and issues related
to antibiotic pharmacokinetics or of reimburse-
ment policies [4,5
&
,21] are beyond the scope of
this review.METHODS
We conducted a literature search (PubMed and
internet) to identify English-language papers up to
23 October 2018 using the MeSH terms: ‘infection’,
‘diabetic foot’, ‘antibiotic stewardship’, ‘consump-
tion’, ‘antibiotic policy’, ‘pathway’, ‘guidelines’ in Copyright © 2019 Wolters Kluwer H
96 www.co-infectiousdiseases.comdifferent combinations [10]. We were most inter-
ested in papers published in the last 2 years.RESULTS
We then grouped the retrieved articles of on antibi-
otic stewardship in DFIs into three major categories:
community cases, hospital cases, and prevention of
DFIs (Table 1). The majority of identified papers
were published between 2 and 10 years ago.Key antimicrobial stewardship actions
The most effective measures relating to antibiotic
stewardship are: making a correct DFI diagnosis;
prescribing an antibiotic regimen with the narrow-
est effective spectrum [18]; and limiting the dura-
tion of antibiotic treatment. Surgically draining and
resecting infected and necrotic material can
improve the outcome of treatment. Although many
clinicians treat DFI for long periods of time, expert
guidance suggest that 1 to 2 weeks is sufficient for
most soft tissue infections, and 4 to 6 weeks is
adequate for osteomyelitis [2,8
&
,22,23]. A recent
randomized trial comparing 6 versus 12 weeks of
antibiotics, without concomitant surgery for dia-
betic foot osteomyelitis, found no differences in
relapse risks [24].
We conducted a retrospective study to investi-
gate whether the route or duration of antibiotic
therapy selected was associated with the likelihood
of a recurrence of a DFI [8
&
]. Among 1018 DFI
episodes in 482 patients, the median total duration
of antibiotic therapy was 20 days. After a median
follow-up of 3 years, 251 episodes (24.7%) recurred,
but neither the duration of antibiotic therapy nor
the use of parenteral treatment affected the risk of
recurrence [8
&
]. Therapy with oral antibiotic agents
can be effective [9] in nonbacteremic mild and
moderate DFIs [2,8
&
,14,22,23], which are by far
the majority of cases. Reports of oral antibiotic
therapy for DFIs, including cases with osteomyelitis,
have been published since 1985 [22]. The results of a
review of 93 DFI cases published in 2006 strongly
supported treatment with oral antibiotic regimens
right from the start in cases of diabetic foot osteo-
myelitis [22]. Data from studies of treatment of
other types of osteomyelitis support the effective-
ness of oral antibiotic therapy [23]. Unfortunately,
there is a persistent reluctance to select oral antibi-
otic regimens for diabetic foot osteomyelitis, largely
based on concern that concomitant arteriopathy
may limit delivery to the foot, or the poor bone
penetration would hamper clinical efficacy. We
found no published data to support these fears.
Available retrospective and prospective analysesealth, Inc. All rights reserved.
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Table 1. Summary of possible measures to promote antibiotic stewardship in diabetic foot infections (authors’ selection)
Setting Group action Individual action Difficulties Reference
Community Statewide policies No specific governmental initiatives found –
Treatment guidelines Less antibiotic use None Lipsky [2]
Diabetic foot centers No published proof of antibiotic prescribing –
Outcome benchmarking Varied case-mix clouds interpretation Milne [32]
Healthcare
institutions
Stewardship programs Less antibiotic use Resource-consuming Lipsky [18]
Withhold antibiotics
before sampling
Reluctance to withdrawal antibiotics Al-Mayahi [38]
Guidelines for
microbiological sampling
None Sotto [41]
Restriction of selected antibiotics Difficult to gain accepted by clinicians Lipsky [18]
Cycling of antibiotic agents No published data for diabetic foot infections –
Clinical pathway Targets mostly amputations and ulcer care Martinez [39]
Link doctors/nurses
(dedicated staff)
Not explored in the literature –
Feedback of results Benefit not specifically reported in the literature Lipsky [18]
Professional wound care None Lipsky [2]
Bacteriophage therapy Minimal published evidence of clinical efficacy Chibber [31]
Topical
antiseptics
No benefit if combined with systemic antibiotics Abbas [29]
Infectiology consultant Availability of ID consultant Uçkay [37]
New diagnostic tools Unclear influence on antibiotic prescribing Lavigne [42]
Prevention Optimal surgical techniques Surgeon and institution-dependent Uçkay [4]
Proper antibiotic prophylaxis None Uçkay [21]
S. aureus decolonization Not specifically analyzed for antibiotic
stewardship
–
Antibacterial vaccines Not specific enough for polymicrobial
infections
–
Pressure off-loading Patient’s compliance Uçkay [3]
Patient education Patient’s compliance and understanding Lipsky [2]
Antibiotic stewardship in the management of DFIs Uçkay et al.have demonstrated the noninferiority of oral medi-
cation (or rejected the superiority of parenteral dos-
ing) [1–4,5
&
,22].Gaps in research
Data available from published studies and expert rec-
ommendations still leave questions about optimal
therapeutic approaches, the answer to which might
provide methods to reduce unnecessary antibiotic
therapy. For examples, results of some as yet unpub-
lished studies suggest we might be able to treat prop-
erly selected mild DFIs [2] without topical or systemic
antibiotic therapy. Although it was previously
assumed that every nonamputated DFI requires treat-
ment with antimicrobials, a recent prospective ran-
domized trial found that mildDFIs couldbe effectively
treated solely with appropriate local wound care [25].
Another example is that many clinicians
broaden the spectrum of their empiric antibiotic Copyright © 2019 Wolters Kluwe
0951-7375 Copyright  2019 Wolters Kluwer Health, Inc. All rights reseregimen after a patient has a clinical recurrence of
a recently treated DFI. We showed that pathogens
causing iterative DFI episodes, in the same anatomi-
cal localization, were less antibiotic-resistant than in
the previous ones. Indeed, in two-thirds of clinical
recurrences the pathogens are different from those
that caused the earlier episodes [26]. Thus, these
data suggest there is no necessity to broadening
the empiric antibiotic spectrum. Similarly, coloni-
zation of the patient with healthcare-associated
methicillin-resistant S. Staphylococcus aureus (MRSA)
rarely requires targeted anti-MRSA therapy [19,27]
and obligate anaerobes are often innocent by-stand-
ers in polymicrobial soft tissue infections that do not
need targeted antibiotic therapy [28].
Treatment with topical antibiotic (or antiseptic)
agents often fails to enhance treatment success of
DFI, especially when combined with systemic anti-
biotic therapy [29]. In a pilot study in which we
randomized patients with DFI to be treated with ar Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com 97
Skin and soft tissue infectionsgentamicin-collagen sponge as an adjunct to sys-
temic antibiotic therapy versus systemic antibiotic
therapy alone, we found no difference in outcomes
[14]. In terms of new classes of therapeutic options,
we currently lack alternative compounds. Results of
studies of treatment with topical antimicrobial pep-
tides (e.g., pexiganan) for DFI were initially promis-
ing [30], but more recent studies have yielded
disappointing results. Likewise, although early
results of therapy with virus bacteriophages appear
promising, it may need to be conducted in conjunc-
tion with systemic antibiotics [31].The community setting
There are administrative approaches that might
improve the use of antimicrobials. Governments
could establish specialized diabetic foot care centers,
which could perhaps reduce inappropriate antibi-
otic prescribing, compared to current dispensers
[12], and provide regular workshops and public
educational lectures. To date, however, there is no
published evidence that treatment in specialized
centers leads to more rational antibiotic therapy.
Benchmarking [32] of antimicrobial use and clinical
outcomes among centers, and publicly reporting
their results, would be challenging and potentially
produce erroneous results because of the variations
in case-mix of DFI seen in different centers. In
contrast, regional or international guidelines, some
of which have been amply validated and are
updated, are available and published [2,33,34].
These guidelines can help investigators to conduct
evidence-based therapies underpinned by antimi-
crobial stewardship principles; while they may
improve treatment outcomes [35].The hospital setting
Treatment in healthcare facilities is the best
explored setting for investigating antibiotic stew-
ardship [36,37]. This is related to several factors,
including a public commitment to improve care
and provide transparency; more frequent treatment
by multidisciplinary teams; the development and
use of clinical pathways; and the presence of aca-
demic physicians interesting in investigating their
local processes and outcomes [36]. Moreover,
healthcare institution more often have ready access
to an infectious diseases/clinical microbiology phy-
sician familiar (and usually involved) with antimi-
crobial stewardship programs. Such programs have
been shown to help reduce cost-effectively antibi-
otic consumption [37]. Another method healthcare
institutions use to control inappropriate antibiotic
use is to mandate constraining the use and duration Copyright © 2019 Wolters Kluwer H
98 www.co-infectiousdiseases.comof empirical preoperative and postoperative antibi-
otic treatment [38]. Presurgical antibiotic treat-
ments in clinically stable patients with DFI are
seldom beneficial and tend to select antibiotic-resis-
tant pathogens. This often results in clinicians
administering broad-spectrum antibiotic therapy,
sometimes related to the fact that the true patho-
gens are masked by antibiotic-resistant organisms
(which are often only colonizers) growing from
specimen cultures. In a review of 2740 orthopedic
infections, including DFIs, we found that presurgi-
cal antibiotic treatment (including single-dose pro-
phylaxis) was associated with a three-fold higher
incidence of antibiotic-resistant nonfermenters
and skin commensals, and negative cultures [38].
Instituting clinical pathways has been a fre-
quently used method to improve outcomes, includ-
ing for DFIs [39]. Although multidisciplinary (or,
more accurately, interdisciplinary) teams have
clearly been shown to be beneficial, they are ham-
pered by three major problems: it is often difficult to
bring the team members together when a patient
needs them outside of a fixed meeting time; the
number of patients requiring evaluation often
exceeds the capacity of fixed meetings; team meet-
ings are time-consuming, usually unremunerated
and key members may be absent. Order-sets [36]
are another powerful tool to rapidly implement
‘bundles’ (a package of orders designed to ensure
uniform processes) and improve outcomes. Recent
published papers have mainly reported on clinical
pathways targeted at all foot problems, especially
treating or preventing ulcers [40], reducing lower
extremity amputations [39] or avoiding or shorten-
ing hospital stays [40]. There are few studies primarily
designed to improve antibiotic treatment of DFI.
Sotto et al. [41] demonstrated that employing
expanded guidelines and education led to a signifi-
cant decrease in the number of bacteria and multi-
drug-resistant organisms per foot infection sample.
In parallel, therewas an associated cost savings of s14
914 related to a reduced microbiology laboratory
workload and another s109 305 because of reduced
prescribing of extended-spectrum antibiotics [41].The role of microbiological diagnostic tests
New molecular diagnostic methods have revealed
the more complex microbiology of DFI than was
appreciated with standard culture methods, but it is
not yet clear whether this information will contrib-
ute to antibiotic stewardship [42], as the clinical
importance of the increased number of species iden-
tified by these methods remains to be elicited. We
also have explored the possible use of antistrepto-
lysin antibodies for the serological identification ofealth, Inc. All rights reserved.
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Antibiotic stewardship in the management of DFIs Uçkay et al.streptococci (with subsequent reduction of the anti-
biotic spectrum to penicillins) [43], but it does not
appear to be of any practical use in DFI. Pro-calcitonin
could be promising, but its benefit in reducing antibi-
otic consumption in DFI needs to be evaluated more,
because several studies deny its diagnostic accuracy in
localized orthopedic infections promising without
systemic inflammation, including DFI [44].
In addition, there are some rules regarding the
handling of already established microbiological
tests, which all add to antibiotic stewardship. For
instance, bone culture is only needed when osteo-
myelitis is suspected and infected bone remains in
the tissue. In clinically stable patients it is preferable
to collect specimens after an antibiotic-free interval
of 1 to 2 weeks and via an image-guided technique
or during surgical intervention [45]. Cultures of soft-
tissues (even deep specimens close to bone) or sinus
tract cultures do not correlate accurately with bone
pathogens. Also, clinicians should avoid collecting
specimens with swabs, as they are frequently con-
taminated with skin flora and do not allow for
histological examination. Close collaboration
between clinicians and microbiology laboratory per-
sonnel regarding the clinical disease, location, and
type of biopsy specimens, and proper transfer of
specimens will produce the most accurate results.
These steps may specifically help in interpreting
culture results and avoiding unnecessary antimicro-
bial susceptibility testing for commensal skin flora.
Clinician–microbiologist interactions can also opti-
mize weighting the results of present and previous
culture results (if available), and in decision-making
for appropriate treatment duration.Antibiotic reduction via prevention and
evidence-based surgery
Prevention of infection is an obvious way to reduce
antibiotic consumption. In particular, prolonged or
exaggerated preoperative antibiotic prophylaxis is
unnecessary for most patients with diabetes who
undergo surgery for noninfectious problems such
as fractures [46] or correction of anatomical alter-
ations (induced by the neuropathy [1–4,5
&
] inher-
ent to practically all patients with chronic diabetes).
Proper surgical technique and expertise are impor-
tant in reducing postoperative infections, but assess-
ing these is subjective and difficult [4]. Employing
excellent surgical technique, such as maintaining
effective hemostasis, gentle tissue handling,
removal of devitalized tissue, and dead space eradi-
cation, reduces surgical site infections [46]. For
established DFIs, in most cases the cavity should
be left open for secondary wound healing, as pri-
mary wound closure increases the risk of persistent Copyright © 2019 Wolters Kluwe
0951-7375 Copyright  2019 Wolters Kluwer Health, Inc. All rights reseinfection. Finally, a longer duration of surgery is a
strong predictor of surgical site infections [21]. Opti-
mizing surgical preparation and intraoperative tech-
niques can improve outcomes and can be learned
[46].Promising avenues of research
Information from recently published literature
offers new measures for preventing SSI and reducing
inappropriate antibiotic treatment. Although some
results appear to be contradictory at the present,
they offer possibilities for future research.
Duration of antibiotic treatment for
residual stump osteitis after amputation
In current practice, antibiotic prescribing after com-
plete toe amputation ranges from a few days of oral
therapy to several weeks of intravenous therapy.
Kowalski et al. [47] demonstrated that patients with
a positive culture of the resection margin for residual
osteomyelitis had more failures than those without
(44 vs. 15%, despite 2 weeks of antibiotic therapy in
both arms). Atway et al. [48] reported a 41% inci-
dence of positive bone culture margins among 27
trans-osseous amputations, compared to a 23% fol-
lowing disarticulation. The presence of positive mar-
gins was associated with worse outcomes, again
despite 25 days of postsurgical antibiotic therapy.
More recently, Mijuskovic et al. [49] suggested that
the assessment of residual bone infections should
perhaps not only rely on cultures, as positive
cultures without concomitant histological confir-
mation might overestimate the true rate of
osteomyelitis, presumably related to specimen con-
tamination at the time of surgery. A definite answer
to this question certainly will also influence future
antibiotic recommendations.
Use or oral b-lactam antibiotics for diabetic
foot osteomyelitis
Many experts in orthopedic infections avoid order-
ing oral b-lactam monotherapy for implant-related
orthopedic infections or chronic osteomyelitis,
because of their reported limited oral bioavailability
and poor bone penetration from in vitro assessments
[50]. By analogy, most experts argue against using
any oral b-lactam for DFI, especially in the context
of osteitis. However, oral amoxicillin/clavulanic
acid is among the most frequently administered
b-lactams for DFI worldwide [8
&
,9,40]. Many prac-
tice-oriented recommendations [2] mention it as a
valuable alternative for mild and moderate DFI. In
light of the potential benefit for antibiotic
stewardship programs, oral b-lactams should be
further explored.r Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com 99
Table 2. Ten major rules for antimicrobial stewardship in diabetic foot infection (DFI)
Prevent DFI: Closely monitor diabetic patients at risk for infection and optimize all aspects related to foot care, including appropriate foot
ware, nail and skin care and treatment of any wounds.
Diagnosing DFI correctly: Be precise and consistent when diagnosing, and describing the severity of, infection.
Exclude noninfectious causes of foot inflammation: These include trauma, gout/pseudogout, Charcot neuro-osteoarthropathy, fracture,
phlebothrombosis, and venous stasis.
Identify causative pathogens: Send samples of tissue (not swabs) and preferably bone (for suspected osteomyelitis). Review results of any
previously obtained cultures. Attempt to differentiate pathogens (requiring treatment) from colonizing or contaminating organisms.
Differentiate between soft-tissue and bone infection: This helps in making decisions with respect to medical versus surgical, urgency of, and
duration of, treatment.
Ensure specialist consultation for most moderate and all severe infections: Evaluate and individualize treatment options for each patient. In
complex cases, involve specialists (or optimally multidisciplinary teams), especially surgeons.
Choose an effective antibiotic regimen with the narrowest spectrum: For empiric, and especially definitive, therapy select an antibiotic
regimen based on the likely or proven: causative pathogen(s); their antibiotic susceptibilities; and, evidence of efficacy for DFIs. Consider
testing in cases of reported ‘penicillin allergy’.
Optimize patient-related effectiveness of antibiotic therapy: Evaluate for factors such as adherence to the treatment regimen, impaired
gastrointestinal absorption, key comorbidities (obesity, renal failure), and presence of clinically significant peripheral arterial disease in
affected limb.
Medical therapy – as long as necessary and as short as possible: For most mild and moderate soft tissue infections 1–2 weeks of therapy is
sufficient. For osteomyelitis with residual infected bone, prescribe no more than 6 weeks of antibiotic therapy. Consider shorter treatment
durations if infection resolves quickly.
Surgical treatment – can limit need for antibiotic therapy: Draining abscesses and resecting infected bone can limit the duration of antibiotic
therapy required.
Skin and soft tissue infectionsScreening for Staphylococcus aureus
carriage with subsequent decolonization
S. aureus carriage in a patient or treating clinician is
not only a nosocomial risk for (staphylococcal)
surgical site infections in general surgery, but poten-
tially also a risk for iterative communitary staphylo-
coccal soft-tissue infections [51]. There is still a
debate as to whether S. aureus in the anterior nares
and in a diabetic foot wound of the same patient are
concordant [52] or not [53]. As a group, patients
with orthopedic conditions appear to benefit from
attempts to ‘search-and-destroy’ S. aureus coloniza-
tion, both in reduction of surgical site infection and
in a cost-saving [21]. However, there is as yet no
literature that has specifically looked at this issue for
DFI surgery.CONCLUSION
Available literature concerning antibiotic steward-
ship specifically designed for DFI patients is unfor-
tunately sparse and further research is greatly
needed. Table 2 recapitulates and summarizes our
10 rules of antibiotic stewardship in DFIs. Among all
possible approaches, general efforts to prevent DFIs
and individualized reduction of unnecessary or
inappropriate antibiotic use are probably the best
current practices. We need further research for
these, and other suggested approaches.
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